Optimata Ltd., developer of the proprietary Optimata Virtual Patient(R) technology to navigate drug development, announced today that a scientific paper based on research carried out by company scientists will be published in the prestigious "Cancer Research" Journal 2008; edition 68: (21), on November, 1st 2008.

Optimata Ltd. announced today that it has been granted U.S. Patent 7,418,374, entitled: "Treatment protocol generation for diseases related to angiogenesis".

Optimata Ltd. announced today that it has been granted U.S. Patent 7,266,483 for a system and method that models granulopoiesis and that can optimize drug therapies in order to reduce or prevent neutropenia.

Optimata Ltd. announced today that it has been granted U.S. Patent 7,133,814 for inventing a system that models the development of thrombopoiesis in humans. The invention enables simulating the thrombopoietic process in virtual patients where different therapies are applied.

Optimata Ltd. announced today the successful results of a clinical study for the prediction of individualized patient response to chemotherapy drugs. The study used Optimata's computerized technology known as the Virtual Cancer Patient Engine (VCP).